Data from Pharmawand - Curated by EPG Health - Date added 15 March 2019

Daiichi Sankyo and Esperion Therapeutics announced that results from the 2,230 patient, 52-week, Phase III long-term safety study of ETC 1002 (bempedoic acid) in dyslipidaemia were published in NEJM. The NEJM publication highlights results from the primary endpoint of adverse event rates over 52-weeks along with key efficacy endpoints at 12-weeks. It shows that bempedoic acid significantly lowered LDL-C by 18.1% (p<0.001) on background maximally tolerated statin therapy, significantly reduced hsCRP, an important marker of the underlying inflammation associated with cardiovascular disease by 22% and that treated patients showed lower rates of new-onset or worsening of diabetes compared with those on placebo (3.3% vs 5.4%). It also showed the drug did not lead to higher overall adverse events compared with placebo (78.5% vs 78.7%), and the proportion of patients with reported serious adverse events was small and similar compared with placebo (14.5% vs 14.0%). Bempedoic acid did not lead to increased discontinuation rates due to muscle-related adverse events of importance, myalgia and muscle weakness compared to placebo (2.1% vs 1.9%) and it showed fewer adjudicated major adverse cardiac events compared with placebo (4.6% vs 5.7%). Finally it was observed to be well-tolerated.

See: "Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol" Kausik K. Ray et al. N Engl J Med 14 March 2019; 380:1022-1032 DOI: 10.1056/NEJMoa1803917

Comment: Bempedoic acid is being developed as a convenient, once-daily, oral therapy for the treatment of patients with elevated LDL-C. Bempedoic acid and the bempedoic acid / ezetimibe combination are currently undergoing regulatory review for marketing authorisation by the European Medicines Agency (EMA). A decision is expected during the first half of 2020.


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Oral Anticoagulation Reversal

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.



See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Load more

Related Content